中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

90 records (took 0.016 seconds)

    RECEPTOR-SELECTIVE LYMPHOTOXIN DEVIANTS
    3.
    发明申请
    RECEPTOR-SELECTIVE LYMPHOTOXIN DEVIANTS 审中-公开

    公开(公告)号：WO2006066463A1

    公开(公告)日：2006-06-29

    申请号：PCT/CN2004/001522

    申请日：2004-12-24

    IPC: C07K14/525 ,  C12N15/28 ,  A61K38/19 ,  A61P33/00 ,  A61P35/00

    CPC classification number: C07K14/5255 ,  A61K38/00

    Abstract: This invention discloses some receptor-selective lymphotoxin (LT) mutants and the ratio, the ability of these lymphotoxin mutants combining with the human TNFRI to that with the human TNFRII, is more than 10. The preparation method and the use of the above said LT mutants are also disclosed. In this invention, the LT mutants bind to the TNFRI selectively and that decreases the binding to the TNFRII in a large range, thereby the toxic effect which may be caused by the TNFRII will be reduced.

    DETOXIFIED TNF AND METHOD OF PREPARING
    4.
    发明申请
    DETOXIFIED TNF AND METHOD OF PREPARING 审中-公开
    脱氧TNF及其制备方法

    公开(公告)号：WO2004099244A2

    公开(公告)日：2004-11-18

    申请号：PCT/DK2004000329

    申请日：2004-05-06

    Applicant: PHARMEXA AS ,  BRATT TOMAS ,  KLYSNER STEEN ,  NIELSEN FINN ,  MOURITSEN SOEREN ,  VOLDBORG BJOERN

    Inventor： BRATT TOMAS ,  KLYSNER STEEN ,  NIELSEN FINN ,  MOURITSEN SOEREN ,  VOLDBORG BJOERN

    IPC: A61K38/00 ,  A61K39/00 ,  C07K14/525 ,  C12N15/28

    CPC classification number: A61K39/0005 ,  A61K38/00 ,  A61K39/001 ,  A61K2039/523 ,  A61K2039/5256 ,  A61K2039/53 ,  C07K14/525

    Abstract: The present invention provides for an immunogenic analogue of a human TNFalpha protein, wherein said analogue comprises an immunogenized monomeric TNFalpha polypeptide or TNFalpha di- or trimer, and wherein the analogue further comprises a toxicity reducing or abolishing mutation selected from the group consisting of Y87S, D143N or A145R, the amino acid numbering setting out from the N-terminal valine in human TNFalpha. The invention also provides for a nucleic acid fragment encoding the analogue as well as to vectors and transformed cells useful in the preparation of the analogue. Also disclosed are methods of down-regulating TNFalpha in a subject in need thereof.

    Abstract translation: 本发明提供人TNFα蛋白的免疫原性类似物，其中所述类似物包含免疫原化的单体TNFα多肽或TNFα二或三聚体，并且其中所述类似物还包含毒性降低或消除突变，其选自Y87S， D143N或A145R，人TNFα中N-末端缬氨酸的氨基酸编号。 本发明还提供编码类似物的核酸片段以及用于制备类似物的载体和转化细胞。 还公开了在有需要的受试者中下调TNFα的方法。

    PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1
    6.
    发明申请
    PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 审中-公开
    肽和相关的分子到达1

    公开(公告)号：WO02092620A3

    公开(公告)日：2003-08-21

    申请号：PCT/US0215273

    申请日：2002-05-13

    Applicant: AMGEN INC

    Inventor： MIN HOSUNG ,  HSU HAILING ,  XIONG FEI

    IPC: C12N15/09 ,  A61K38/00 ,  A61P17/02 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P37/06 ,  C07K1/04 ,  C07K5/113 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07K14/47 ,  C07K16/44 ,  C07K19/00 ,  C12N1/21 ,  C12N15/10 ,  C12N15/28 ,  C40B40/02 ,  C07K14/52 ,  A61K38/19 ,  C07K14/525 ,  C12N5/10

    CPC classification number: C07K7/08 ,  A61K38/00 ,  A61K38/10 ,  C07K1/047 ,  C07K14/001 ,  C07K14/4702 ,  C07K14/7151 ,  C07K16/241 ,  C07K2319/30 ,  C07K2319/74 ,  C12N15/1037 ,  C40B40/02

    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz Lz wherein z is an amino acid residue and z is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae a a a CDa La a a Ca a a (SEQ.ID.NO:100), b b b Cb b Db Lb b b b b Cb b b (SEQ.ID.NO:104) c c c Cc Dc Lc c c c c c Cc c c (SEQ.ID.NO:105) d d d Cd d d WDd Ld d d Cd d d (SEQ.ID.NO:106) e e e Ce e e De Le Ke Ce e e e (SEQ.ID.NO:107) f f f Kf Df Lf f Qf f f (SEQ.ID NO:109) wherein the substituents are as defined in the specification. The invention further comprises compositions of matter of the formula (X )a-V -(X )b wherein V is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.

    Abstract translation: 本发明涉及调节TALL-1活性的治疗剂。 根据本发明，TALL-1的调节剂可以包含氨基酸序列Dz 2 Lz 4，其中z 2是氨基酸残基，z 4是苏氨酰基或异亮氨酰基。 示例性分子包含下式的序列a 1 a 2 a 3 3 a 3 C 8 La 8 a 9 A 10 C 12 a 13 N 14（SEQ ID NO： .ID.NO:100），b 1 b 2 b 3 cb 5 b 6 d b 8 b b b b b 12 b 13 b < 14 C b 16 b 17 b（18）（SEQ.ID.NO:104）c 1 c c c 3 C c 5 C c C 10 > C 11 C 12 C 13 C 16 C 17 C（SEQ ID NO：105）d 1 d 2 d 3 Cd <5> d 6 d <7> WDd 10 D 13 d 14 d 15 Cd 16 d 17（SEQ.ID.NO:106）e <1>电子<2>电子<3> CE <5>电子<6>Ë<7>德<9>勒<11>柯<13> CE <15>电子<16>Ë<17>电子<18 （SEQ.ID.NO:107）f 1 f 2 f 3 K f 5 D f 7 L f 9 f 10 Q f 12 f 13 f 14 （SEQ ID NO：109），其中取代基如说明书中所定义。 本发明还包括式（X 1）aV 1 - （X 2）b的物质组合物，其中V 1是共价连接到一个或多个上述TALL-1 调节物质的组成。 载体和TALL-1调节组合物可以通过TALL-1调节部分的N末端或C末端连接。 优选的载体是Fc结构域，优选的Fc结构域是IgG Fc结构域。

    COMBINATION THERAPY
    7.
    发明申请
    COMBINATION THERAPY 审中-公开
    组合治疗

    公开(公告)号：WO02078766A3

    公开(公告)日：2003-05-22

    申请号：PCT/US0208057

    申请日：2002-03-14

    Applicant: GENENTECH INC

    Inventor： GREWAL IQBAL

    IPC: A61K45/00 ,  A61K39/395 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  C07K16/28 ,  C12N15/28 ,  C12P21/08 ,  A61K39/00

    CPC classification number: C07K16/2878 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2887 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/76

    Abstract: The invention provides for the treatment of diseases or disorders characterized by cells expressing the CD40 membrane glycoprotein. The invention provides methods for the treatment of various diseases or disorders characterized by cells expressing CD40 with a combination of an agent causes the depletion of cells expressing CD40 and a second agent which causes the depletion of cells expressing the CD20 membrane antigen. Pharmaceutical compositions and articles of manufacture such as kits comprising the agents and combinations thereof are also provided.

    Abstract translation: 本发明提供治疗以表达CD40膜糖蛋白的细胞为特征的疾病或病症。 本发明提供了治疗各种疾病或病症特征的方法，其特征在于表达CD40细胞的细胞与药物的组合导致表达CD40的细胞的消耗，以及引起表达CD20膜抗原的细胞的消耗的第二药剂。 还提供药物组合物和制品，例如包含试剂及其组合的试剂盒。

    INDUCTION OF TOLERANCE BY APOPTOTIC AND/OR NECROTIC CELLS
    9.
    发明申请
    INDUCTION OF TOLERANCE BY APOPTOTIC AND/OR NECROTIC CELLS 审中-公开
    诱导细胞凋亡和/或坏死细胞的耐受

    公开(公告)号：WO02060376A3

    公开(公告)日：2002-11-14

    申请号：PCT/IL0200089

    申请日：2002-01-31

    Applicant: TOLAREN ,  MEVORACH DROR

    Inventor： MEVORACH DROR

    IPC: A61K35/12 ,  A61K35/26 ,  A61K35/28 ,  A61K39/00 ,  C12N15/19 ,  C12N15/28 ,  A61K45/00 ,  A61K47/00 ,  C12N5/00 ,  C12N5/02

    CPC classification number: A61K39/0008 ,  A61K35/15 ,  A61K35/26 ,  A61K35/28 ,  A61K2039/515

    Abstract: The present invention is directed to a method of inducing tolerance to self-antigens in a subject having an autoimmune diseases. In particular, the invention provides a pharmaceutical composition and method of use thereof for the modulation of immunogical activity in an animal subject. Said modulation may be an increased tolerance to self apoptotic cells, a reduction in the tissue levels of autoantibodies associated with apoptotic cells, a reduction in the tissue levels of autoantibodies associated with an autoimmune disease, a reduction in the level of inflammation and inflammatory mediators associated with an autoimmune disease, a reduction in the level of tissue damage associated with an autoimmune disease, or a combination thereof.

    Abstract translation: 本发明涉及在患有自身免疫疾病的受试者中诱导对自身抗原的耐受性的方法。 具体而言，本发明提供了用于调节动物受试者的免疫活性的药物组合物及其使用方法。 所述调节可以是对自身凋亡细胞的增加的耐受性，与凋亡细胞相关的自身抗体的组织水平的降低，与自身免疫疾病相关的自身抗体的组织水平的降低，炎症水平的降低和炎症介质相关 与自身免疫性疾病，与自身免疫性疾病相关的组织损伤水平降低或其组合。

Patent Agency Ranking